Effect of OFA in Laparoscopic Gastrectomy
Postoperative Pain

About this trial
This is an interventional prevention trial for Postoperative Pain
Eligibility Criteria
Inclusion Criteria:
- Patients over 19 years who underwent laparoscopic gastrectomy for gastric cancer
Exclusion Criteria:
- Patients with a history of allergic reactions to drugs
- Patients with a history of drug addiction
- Patients with chronic pain who require analgesics
- Patients with cancer other than the stomach
- History of hospitalization for psychiatric disorders
- Patients with sleep apnea
- Preoperative pulse oximetry (SpO2) < 95 %
- Moderate or severe hepatic impairment
- bradycardia (HR<50bpm), hypotension, atrioventricular block, intraventricular or sinus block
- Body mass index over 35 kg/m2
- Blood clotting disorders
- Pregnant/lactating women
- Cognitive impairment
- Unable to read consent form (eg illiterate, foreigner, etc.)
Sites / Locations
- Gangnam Severance Hospital
- Gangnam Severance Hsopital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
OFA group
Control group
Dexmedetomidine and lidocaine are administered during anesthesia, and opioid is not used. For induction, 1 μg/kg of Dexmedetomidine is administered over 10 minutes and 1mg/kg of lidocaine is administered intavenously (bolus). This is followed by continuous intravenous infusion of dexmedetomidine at a rate of 0.2-0.7 μg/kg/h and infusion of lidocaine at the rate of 1 mg/kg/h.
Remifentanil is infused during anesthesia, and target-controlled infusion (TCI) is performed according to the Minto model. During indcution of anestheisa, target concentration of remifentanil is set within 3-5 ng/mL. After intubation, target concentration is adjusted within the range of 2-8 ng/mL.